A Phase I, Single-centre, Non-randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-Selumetinib in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 14 Oct 2016
Price : $35 *
At a glance
- Drugs Selumetinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 14 Oct 2016 Results published in the Clinical Therapeutics
- 01 Nov 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.